Abstract 2934
Background
MicroRNAs are examined for clinical utility in active germ cell malignancies (GCM). miR-371a-3p (miR371) has a very high specificity and high sensitivity for the detection of GCM. However, in teratoma neither tissue nor serum/plasma are miR371 positive. miR375 is overexpressed in teratoma tissue, but detectability in blood and its utility is unknown.
Methods
GCM patients (pts) enrolled from 10-2016 to 03-2019 in the GU biobank program at British Columbia Cancer were analyzed for plasma miR371/miR375 expression by RT-PCR and quantified by ΔΔCT method. Spike-in cel-miR-39-3p, miR-451 and miR-30b-5p were used as quality/internal controls. Sensitivity, specificity, PPV, NPV, AUC of the ROC of miR375 in detecting teratoma were analyzed.
Results
miR375 expression was measured in 69 pts of whom 15 (22%) had pathologically confirmed residual teratoma post-chemotherapy, 4 (6%) residual post-chemotherapy mass without teratoma, 8 (11%) no evidence of residual disease post-chemotherapy, 15 (22%) metastatic seminoma and 27 (39%) CSI with no evidence of tumor. miR375 expression was significantly higher in pts with residual teratoma-post chemotherapy than in non-teratoma (p < 0.0001). Concurrent miR371 and miR375 expression was evaluated in 17 pts with metastatic nonseminoma prior to and post-chemotherapy. miR371 correlated with viable GCM and disappeared after chemotherapy in all but one pt (presenting residual choriocarcinoma). Post-chemotherapy miR375 was unchanged or increased from pre-chemotherapy samples in 85% of pts with pathologically confirmed post-chemotherapy teratoma and remained low in 90% of patients with either complete response or non-teratoma after chemotherapy. Sensitivity of miR375 was 93% (95% CI: 68-99), specificity 75% (95% CI: 43-95), NPV 90% (95% CI 95%: 57-98), PPV 82% (CI 95%: 63-93) and the AUC of miR375 in the post-chemotherapy setting was 0.93 (95% CI: 0.83-1.0; p < 0.0001).
Conclusions
miR375 is overexpressed and detectable in the plasma of pts with teratoma while its expression is significantly lower in nonseminoma pts without teratoma or in seminoma. The evaluation of miR371/miR375 may be clinically useful to guide therapeutic decisions (surgery or chemotherapy). Larger studies are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5579 - Quality of informed consent in clinical trials patients
Presenter: Gianluca Catania
Session: Poster Display session 3
Resources:
Abstract
5147 - Patient's rights: Where do we stand?
Presenter: Maja Kozuh
Session: Poster Display session 3
Resources:
Abstract
1279 - The oncology nurse coordinator’s role in a digestive oncology department: Impact on patient and hospital
Presenter: Fouad Awada
Session: Poster Display session 3
Resources:
Abstract
1670 - Nursing model for a breast cancer unit at the Catalan Institute of Oncology
Presenter: Ana Rodriguez-ortega
Session: Poster Display session 3
Resources:
Abstract
3936 - Role of cancer nurse in the prevention and control of acute deterioration for oncohematologic patient
Presenter: Raquel Azor Portolés
Session: Poster Display session 3
Resources:
Abstract
2789 - Standardized nursing care in the department of radiotherapy of a network of cancer centres
Presenter: José Delgado
Session: Poster Display session 3
Resources:
Abstract
4482 - Exploring anxiety, depression and quality of life of ambulatory cancer patients during chemotherapy.
Presenter: Theodoula Adamakidou
Session: Poster Display session 3
Resources:
Abstract
3075 - Implementing a Cancer Survivorship Program for Individuals with Recurrent Breast Cancer
Presenter: Darcy Burbage
Session: Poster Display session 3
Resources:
Abstract
3869 - The perceptions of parents/guardians regarding their child/adolescent’s experience of reflexology or non-specific foot massage The perceptions of parents/guardians regarding their child/adolescents experience of reflexology or non-specific foot massage
Presenter: Patricia Fox
Session: Poster Display session 3
Resources:
Abstract
4064 - Quality of life in survivors of adult haematological malignancies
Presenter: Anita Immanuel
Session: Poster Display session 3
Resources:
Abstract